NASDAQ:INCY
Incyte Corporation Stock News
$54.08
+0.320 (+0.595%)
At Close: May 06, 2024
2 Biotech Stocks That Could Make You Richer
01:07pm, Friday, 04'th Nov 2022 The Motley Fool
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.
2 Biotech Stocks That Could Make You Richer
09:07am, Friday, 04'th Nov 2022
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors.
Incyte A Buy As Revenue From Opzelura Ramps
04:36pm, Wednesday, 02'nd Nov 2022
Incyte reported 20% y/y product revenue growth in Q3 2022. Opzelura revenue grew $38 million y/y.
Incyte (INCY) Q3 Earnings and Revenues Miss Estimates
12:35pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates
12:03pm, Tuesday, 01'st Nov 2022
Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.
Incyte Corporation (INCY) Q3 2022 Earnings Call Transcript
11:44am, Tuesday, 01'st Nov 2022
Incyte Corporation (NASDAQ:INCY ) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Christine Chiou - Head, Investor Relations Hervé Hoppenot - Chairman, President and
Incyte (INCY) Q3 Earnings and Revenues Miss Estimates
09:47am, Tuesday, 01'st Nov 2022
Incyte (INCY) delivered earnings and revenue surprises of -16.67% and 2.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More
08:07pm, Monday, 31'st Oct 2022 Zacks Investment Research
Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
05:08pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Incyte's (INCY) third-quarter 2022 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
Zacks.com featured highlights include e.l.f. Beauty, Monarch Casino & Resort, Incyte and Hubbell
01:15pm, Thursday, 27'th Oct 2022 Zacks Investment Research
e.l.f. Beauty, Monarch Casino & Resort, Incyte and Hubbell are part of the Zacks Screen of the Week article.
Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know
02:02pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights The Williams Companies, Interactive Brokers, Incyte, Hubbell and Lamb Weston Holdings
12:26pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
The Williams Companies, Interactive Brokers, Incyte, Hubbell and Lamb Weston Holdings are part of the Zacks top Analyst Blog.
4 Top-Rated Stocks to Buy Now for Solid Earnings Growth
12:01pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Invest in stocks like e.l.f. Beauty (ELF), Monarch Casino & Resort (MCRI), Incyte (INCY) and Hubbell (HUBB) at the moment for superb earnings growth.
4 Top-Rated Stocks to Buy Now for Solid Earnings Growth
09:02am, Wednesday, 26'th Oct 2022
Invest in stocks like e.l.f. Beauty (ELF), Monarch Casino & Resort (MCRI), Incyte (INCY) and Hubbell (HUBB) at the moment for superb earnings growth.
Earnings Preview: Incyte (INCY) Q3 Earnings Expected to Decline
02:01pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
